FIGURE 5.

Drp1‐inhibition in FRDA patient fibroblasts trends toward decreasing both mitochondrial fragmentation and ATP levels. At 72 h, 1 µM TAT‐P110 trends toward decreasing the number of mitochondrial fragments in FRDA patient fibroblasts (A–C) but does not impact the level of FXN (D–E). This drug decreases the number of (Ser616) phospho‐Drp1 clusters (F–H) but does not impact the levels of (Ser616) phospho‐Drp1 or Drp1 (I–J). TAT‐P110 trends toward decreasing ATP levels (K). *p < .05, n.s. not significant